News

2017 in Review – A Year of Growth and Addition of Key Team Members at DBM

As DBM reflects on a strong 2017 and hello to a promising 2018, DBM said hello to several new faces in both its labs and offices. In the past year, DBM has added new staff and new capabilities. In early 2017, DiscoveryBioMed hired Matthew Redmann, PhD to the post of Head of Business Development and Senior Scientist. As a recently graduated Ph.D. from the University of Alabama at Birmingham (UAB), Matthew brings with him a quality publication record and substantive interests in the business of science and how to translate discoveries at the bench to useful applications in the world. Matt is originally from Appleton, WI. Shortly after, Lawrence Greer, J.D., LLM was appointed as Chief Financial Officer to oversee and manage the increasing complexity of DBM’s financial dealings. Lawrence earned his J.D from the University of Alabama School of Law and brings with him significant legal and business experience in the biotechnology and finance realms. Lawrence is originally from Birmingham, AL. Alongside these additions, DBM promoted a long-term and valued intern, Albert “Os” Nakayama,...

Read More

Update: Human ADPKD Kidney Cell Platforms – Progress to Date

Prelude This post is meant to serve as an abbreviated version of an internal White Paper and is provided as an update to our efforts here at DiscoveryBioMed, Inc. (DBM, Inc.) to continue to optimize and develop human ADPKD kidney cell platforms. We are ‘learning by doing’ as always, and we wanted to present some new findings and current status of products in development. A Mixed Cell Population Is Key to “Cystogenesis Functionality” One confounding issue in the practice of isolating, growing, genotyping and characterizing single cyst-derived primary cultures and multicystic/microcystic tissue-derived primary cultures is that not all of the primary cultures from individual kidneys form cysts or are capable of cystogenesis. This is puzzling in light of the fact that they all derive from the same human ADPKD donor kidney tissue. Having said that, with each donor, we do have primary cultures that indeed form cysts. During the characterization of all primary cultures from a given donor in 3D Biogels, we also seed some cells from each culture on TC plastic so as to...

Read More

Q2 2017 Update: DBM Sends Delegates to BIO and RESI Conferences in San Diego

As mentioned in the Q1 2017 update, it is an exciting year thus far for DiscoveryBioMed with the acquisition of a BioTek Cytation 5 anchored automated system. In order to market these new capabilities and build new relationships with potential clients and partners, DBM sent a team of delegates to both the BIO International Convention and at RESI (hosted by Life Science Nation) in San Diego this past July. Last year at BIO 2016, DBM was invited to exhibit at the BIO Innovation Zone with other select companies that are pushing the boundaries on scientific innovation and translation to the marketplace. Last year at the BIO Investor Forum, DBM was sponsored by the NIH NIDDK to present the latest data from our Adiponectin Inducer program. This year in an effort to further increase DBM’s reach, delegates looked outside the formal BIO convention for additional meetings and attended another conference called RESI. Between these two conventions and over the course of two and a half days, DBM’s delegates Erik Schwiebert, Lawrence Greer, and Matthew Redmann had...

Read More

Q1 2017 Update: DBM Invests in Cytation 5 Anchored Automated System

Discovery BioMed prides itself on utilizing the latest technology platforms and offering services based on these advanced systems. In H1 2017 DBM invested in a BioTek Cytation 5 anchored automatic robotics system supported by BioTek’s BioSpa 8 and a BioTek plate washer. Together this system provides high-content automated fluorescence, luminescence, brightfield imaging and plate reading modalities. After an initial period of set-up and optimization, DBM is now utilizing this platform for both its CRO services and R&D arms. One service that has proven popular with our large biopharma clients, leverages DBM’s expertise in renal biology and is a demonstration of the types of assays we offer is DBM’s in vitro 3D cyst formation assay. This is assay is directed towards clients and researchers with a principle interest in human renal diseases that exhibit cystogenesis as part of their pathology. As with all research projects undertaken by DBM, we base the assay on human tissue platforms. This enables greater translatability of the results and a better likelihood of eventual clinical success. This assay in particular relies...

Read More

Q4 2016 Update – DBM Participates at BIO’s 2016 International Conference and BIO’s 2016 Investor Forum, Continues an Active Intern Program

In June 2016, DBM's Dr. Erik Schwiebert and Dr. John Streiff, with support from our long-time consultant, Dr. Douglas Hay, traveled to San Francisco to participate in the annual BIO International Meeting. There, DBM met with over 40 companies within and outside the BIO Partnering Forum. The NIH NIDDK also nominated and supported DBM at the convention with an Exhibit Kiosk in the NIH Innovation Zone. DBM was humbled and grateful for this opportunity. DBM was also an active partner in the BioAlabama exhibit. Additionally, DBM was nominated by the NIH NDDK to participate in the Annual 2016 Bio Investor forum. And, in October, DBM traveled to San Francisco, once again, to present the results from an in vivo study with lead compounds from its Metabolic R&D program. DBM’s presentation was well received and its presence made possible by an NIDDK administrative supplement to an active SBIR award for registration and travel funds. DBM's Dr. Schwiebert declared that "DBM continues to be honored and grateful for the deep support from the NIDDK in our partnering...

Read More

DiscoveryBioMed, Inc. Declares a Sharpened Focus on Renal Cell Biology and Physiology and on Renal Diseases

Through both natural evolution of our R&D programs and within our CRO services business, DiscoveryBioMed, Inc. (DBM, Inc.) has identified a sharpening focus in Renal or Kidney Cell Biology and Physiology and in Renal Diseases over the last year, in 2016, and going forward. We invite interested parties to view our newly redesigned website where this focus is declared and apparent. It is ironic that DBM’s founder, Dr. Erik Schwiebert, first worked on Renal Cell Physiology while a lab technician, first year Ph.D. student, and Ph.D. candidate while in Dr. Bruce Stanton’s laboratory at Dartmouth. “In my very first memories of culturing rodent and human cells, I was involved in establishing primary cultures and growing those cultures and immortal cell lines from the nephron of the kidney so as to study the regulation of epithelial sodium and chloride channels in collecting duct-derived cells,” Erik explained. “I am very familiar with establishing and growing kidney cells as well as studying them and characterizing them. It is therefore not surprising that DBM has also gravitated to that...

Read More